INO
Inovio Pharmaceuticals Inc.
$1.26
-$0.09(-6.67%)
34
Overall
60
Value
9
Tech
34
Quality
Market Cap
$112.66M
Volume
2.12M
52W Range
$1.03 - $2.98
Target Price
$5.96
Order:
Income Statement
| Metric | Trend | Chart | 2016 Dec | 2017 Dec | 2018 Dec | 2019 Dec | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec | 2025 Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| REVENUE | ||||||||||||
| Total Revenue | $35.2M | $42.2M | $30.5M | $4.1M | $7.4M | $1.8M | $10.3M | $832.0K | $217.8K | $65.3K | ||
| Total Revenue | $35.4M | $42.2M | $30.5M | $4.1M | $7.4M | $1.8M | $10.3M | $832.0K | $217.8K | $65.3K | ||
| GROSS PROFIT | ||||||||||||
| Gross Profit | $35.2M | $42.2M | $30.5M | $4.1M | $7.4M | $1.8M | $10.3M | $832.0K | $217.8K | $65.3K | ||
| OPERATING EXPENSES | ||||||||||||
| Operating Expenses | $-111.6M | $126.9M | $124.6M | $115.2M | $131.5M | $303.0M | $277.8M | $144.8M | $112.6M | $86.9M | ||
| Research & Development | $88.7M | $98.6M | $95.3M | $88.0M | $94.2M | $249.2M | $187.7M | $86.7M | $75.6M | $54.2M | ||
| Research Expense | $88.7M | $98.6M | $95.3M | $88.0M | $94.2M | $249.2M | $187.7M | $86.7M | $75.6M | $54.2M | ||
| Selling, General & Administrative | $23.9M | $28.3M | $29.3M | $27.2M | $37.2M | $53.8M | $90.2M | $47.6M | $37.0M | $32.7M | ||
| General & Administrative Expenses | $23.9M | $28.3M | $29.3M | $27.2M | $37.2M | $53.8M | $90.2M | $47.6M | $37.0M | $32.7M | ||
| Salaries & Wages | $-10.5M | $-13.1M | $-10.7M | $10.9M | $15.6M | $26.3M | -- | $10.4M | -- | -- | ||
| Depreciation & Amortization | $-1.7M | $-1.9M | $-3.7M | $3.6M | $3.0M | $3.0M | $3.7M | $2.6M | $1.8M | -- | ||
| Depreciation & Amortization | $-1.7M | $-1.9M | $-3.7M | $3.6M | $3.0M | $3.0M | $3.7M | $2.6M | -- | -- | ||
| Amortization | $-1.4M | $-1.6M | $-1.2M | $10.5M | $10.5M | $10.5M | $10.5M | -- | -- | -- | ||
| Other Operating Expenses | $-111.6M | $-125.9M | $-124.6M | $-1.6M | $-1.0M | $-6.6M | $-2.9M | $-1.8M | -- | -- | ||
| OPERATING INCOME | ||||||||||||
| Operating income | $-77.4M | $-84.6M | $-94.1M | $-111.1M | $-124.1M | $-301.2M | $-267.6M | $-143.9M | $-112.4M | $-86.8M | ||
| EBITDA | $-70.4M | $-84.4M | $-89.7M | $-107.3M | $-149.6M | $-296.6M | $-270.9M | $-135.6M | $-104.5M | $-82.4M | ||
| NON-OPERATING ITEMS | ||||||||||||
| Interest Expense (Non-Operating) | -- | -- | -- | $7.9M | $8.7M | $1.9M | $1.3M | $1.2M | $177.8K | -- | ||
| Interest Income Operating | -- | -- | $2.3M | $2.6M | $3.3M | $3.4M | $4.8M | $8.1M | -- | -- | ||
| Intinc | $1.3M | $1.6M | $920.9K | -- | -- | -- | -- | $8.1M | $4.8M | $2.4M | ||
| Net Non-Operating Interest Income/Expense | $1.3M | $1.6M | $360.8K | $-7.9M | $-8.7M | $-1.9M | $-3.5M | $8.1M | $4.6M | $2.4M | ||
| Gain on Sale of Securities | $139.0K | $215.0K | $20.0K | $-1.8M | $-75.7M | $394.0K | $21.0K | $1.0K | -- | -- | ||
| Other Income/Expense | $-2.1M | $5.2M | $3.3M | $1.3M | $75.1M | $3.3M | $-13.6M | $-1.2M | $-1.7M | $1.0M | ||
| Other Special Charges | $1.1M | $14.8M | $-3.3M | $496.2K | $-704.9K | $343.4K | $-3.9M | $-4.7M | $-355.1K | $-2.1M | ||
| SPECIAL ITEMS | ||||||||||||
| Special Income Charges | -- | $215.0K | $1.3M | -- | -- | -- | -- | $-10.5M | -- | -- | ||
| Impairment of Capital Assets | -- | -- | -- | -- | -- | -- | -- | $10.5M | -- | -- | ||
| PRE-TAX INCOME | ||||||||||||
| EBIT | $-73.7M | $-88.2M | $-94.8M | $-112.9M | $-154.2M | $-301.3M | $-276.4M | $-139.0M | $-107.6M | $-85.4M | ||
| Pre-Tax Income | $-73.7M | $-88.2M | $-94.8M | $-120.8M | $-162.9M | $-303.2M | $-277.7M | $-134.6M | $-106.1M | $-85.5M | ||
| INCOME TAX | ||||||||||||
| Tax Provision | $-501.0K | $-50.0M | $2.2M | $-257.3K | -- | $-3.4M | $-3.6M | $-3.9M | $-565.0K | $-410.0K | ||
| NET INCOME | ||||||||||||
| Net Income | $-74.1M | $-88.2M | $-97.0M | $-119.4M | $-166.4M | $-303.7M | $-279.8M | $-135.1M | $-107.3M | $-84.9M | ||
| Net Income (Continuing Operations) | $-74.1M | $-88.2M | $-97.0M | $-119.4M | $-166.4M | $-303.7M | $-279.8M | $-135.1M | $-107.3M | $-84.9M | ||
| Net Income (Discontinued Operations) | $-74.1M | $-88.2M | $-97.0M | $-119.4M | $-166.4M | $-303.7M | $-279.8M | $-135.1M | $-107.3M | $-84.9M | ||
| Net Income (Common Stockholders) | $-74.1M | $-88.2M | $-97.0M | $-116.3M | $-166.4M | $-303.7M | $-279.8M | $-135.1M | $-107.3M | $-84.9M | ||
| Normalized Income | -- | -- | -- | -- | -- | -- | -- | -- | -- | $-85.9M | ||
| TOTALS | ||||||||||||
| Total Expenses | $-111.6M | $126.9M | $124.6M | $115.2M | $131.5M | $303.0M | $277.8M | $144.8M | $112.6M | $86.9M | ||
| SHARE & EPS DATA | ||||||||||||
| Average Shares Outstanding | $73.2M | $81.8M | $92.5M | $98.7M | $12.9M | $17.4M | $19.9M | $22.2M | $27.2M | $46.9M | ||
| Average Shares Outstanding (Diluted) | $73.2M | $81.9M | $92.5M | $98.7M | $12.9M | $17.4M | $19.9M | $22.2M | $27.2M | $46.9M | ||
| Shares Outstanding | $74.1M | $90.4M | $97.6M | $145.8M | $17.3M | $18.1M | $21.7M | $23.4M | $36.7M | $69.1M | ||
| Basic EPS | $-1.01 | $-1.08 | $-1.05 | $-1.21 | $-12.84 | $-17.4 | $-14.04 | $-6.09 | $-3.95 | $-1.81 | ||
| Basic EPS (Continuing Operations) | -- | $-1.08 | $-1.05 | $-1.21 | $-12.84 | $-17.4 | $-14.04 | $-6.09 | $-3.95 | $-1.81 | ||
| Diluted EPS | $-1.01 | $-1.09 | $-1.05 | $-1.21 | $-12.84 | $-17.4 | $-14.04 | $-6.09 | $-3.95 | $-1.81 | ||
| Diluted EPS (Continuing Operations) | -- | $-1.09 | $-1.05 | $-1.21 | -- | $-17.4 | $-14.04 | $-6.09 | $-3.95 | $-1.81 | ||
| OTHER METRICS | ||||||||||||
| Acquired In Process Rn D | -- | $-7.0M | -- | -- | -- | -- | -- | -- | -- | -- | ||
| Earnings from equity interest | -- | $-7.0M | -- | -- | $-4.6M | $-434.4K | $-2.2M | -- | -- | -- | ||
| Earnings From Equity Interest Net Of Tax | -- | $-7.0M | -- | -- | $-4.6M | $-434.4K | $-2.2M | -- | -- | -- | ||
| Gain On Sale Of Business | -- | -- | -- | -- | $4.1M | -- | -- | -- | -- | -- | ||
| Gain On Sale Of P P E | $1.0M | $1.0M | -- | $6.0K | $227.0K | $89.0K | $1.1M | $466.0K | -- | -- | ||
| Minority Interests | -- | -- | -- | $1.2M | $1.1M | -- | -- | -- | -- | -- | ||
| Other Gand A | $23.9M | $28.3M | $29.3M | $27.2M | $37.2M | $53.8M | $90.2M | $47.6M | $37.0M | $32.7M | ||
| Realized Capital Gain | -- | -- | $-2.0M | -- | -- | -- | -- | -- | -- | -- | ||
| Rent And Landing Fees | $23.9M | $-2.4M | $-3.2M | -- | -- | -- | -- | -- | -- | -- | ||
| Write Down | -- | $-215.0K | $-1.3M | -- | -- | -- | -- | -- | -- | -- | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | INO | $1.26 | -6.7% | 2.12M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Inovio Pharmaceuticals Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW